Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Crucell
|
| gptkbp:addressed |
subcutaneously
|
| gptkbp:appointed_by |
gptkb:hospital
older adults adults over 50 a healthcare setting |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:caused_by |
headache
fever injection site reactions mild side effects |
| gptkbp:contains |
gptkb:live_attenuated_varicella-zoster_virus
|
| gptkbp:covered_by |
most health insurance plans
|
| gptkbp:developed_by |
gptkb:Merck_&_Co.
|
| gptkbp:first_introduced |
gptkb:2006
|
| gptkbp:followed_by |
chickenpox infection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zoster vaccine
|
| gptkbp:is_a |
treatment for postherpetic neuralgia
treatment for shingles |
| gptkbp:is_associated_with |
increased immunity
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_available_on |
gptkb:Shingrix
gptkb:Zostavax |
| gptkbp:is_considered |
safe and effective
a preventive measure a public health priority |
| gptkbp:is_discussed_in |
gptkb:academic_journal
|
| gptkbp:is_effective_against |
chickenpox
other herpes viruses reducing the risk of postherpetic neuralgia reducing the risk of shingles |
| gptkbp:is_evaluated_by |
clinical trials
safety and efficacy |
| gptkbp:is_part_of |
public health initiatives
preventive healthcare vaccination campaigns adult immunization programs adult vaccination schedule herpes zoster prevention strategy |
| gptkbp:is_promoted_by |
health organizations
|
| gptkbp:is_protected_by |
shingles
|
| gptkbp:is_subject_to |
regulatory approval
|
| gptkbp:requires |
two doses
|
| gptkbp:suitable_for |
gptkb:Person
gptkb:CDC healthy adults pregnant women immunocompromised individuals people who have had chickenpox people with severe allergies to components those at risk of shingles |